Recursion announced that the UK Medicines and Healthcare Products Regulatory Agency has cleared a clinical trial application for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies. For REC-3565, the total addressable population could include a range of hematological indications, with approximately 41,000 relapsed and/or refractory patients with chronic lymphocytic leukemia and B-cell lymphomas in the US+EU5 annually. Recursion also announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 inhibitor for small-cell lung cancer and other potential indications. For REC-4539, the total addressable population in the US+EU5 for extensive stage SCLC is approximately 45,000 patients annually.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA
- Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
- Recursion Pharmaceuticals call volume above normal and directionally bullish
- Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader
- Recursion announces first patient dosed in Phase 1/2 trial of REC-1245